Treatment efficacy of idiopathic pulmonary fibrosis depending on the dose difference of pirfenidone
Y. Shin (Seoul, Republic of Korea), C. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), H. Yoon (Seoul, Republic of Korea), Y. Cho (Seoul, Republic of Korea), J. Park (Seoul, Republic of Korea), Y. Lee (Seoul, Republic of Korea), S. Lim (Seoul, Republic of Korea), Y. Lee (Seoul, Republic of Korea), S. Choi (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea), B. Kwon (Seoul, Republic of Korea)
Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. Shin (Seoul, Republic of Korea), C. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), H. Yoon (Seoul, Republic of Korea), Y. Cho (Seoul, Republic of Korea), J. Park (Seoul, Republic of Korea), Y. Lee (Seoul, Republic of Korea), S. Lim (Seoul, Republic of Korea), Y. Lee (Seoul, Republic of Korea), S. Choi (Seoul, Republic of Korea), Y. Kim (Seoul, Republic of Korea), B. Kwon (Seoul, Republic of Korea). Treatment efficacy of idiopathic pulmonary fibrosis depending on the dose difference of pirfenidone. 779
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: